Genmab A/S completed a share‑capital reduction on April 17 2026, canceling 1,900,000 of its own shares and lowering the nominal share capital to DKK 62,350,721. The reduction was registered with the Danish Business Authority and will be reflected in Nasdaq’s system by April 21 2026.
The move is part of a broader capital‑allocation strategy that has seen the company aggressively buy back shares. Management has used share buybacks to return value to shareholders and to optimize the company’s capital structure.
On the same day, Genmab filed updated Articles of Association, granting the board authority to issue new shares, employee warrants, and convertible debt. The update signals flexibility for future capital raising and incentive plans.
A similar reduction occurred on April 10 2025, when 2,076,853 shares were cancelled and the nominal share capital was lowered to DKK 64,120,391, indicating a pattern of active capital management.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.